healthcare - Page 2

How ReWalk Is Capitalizing on Its Big Win

ReWalk Robotics Ltd. (NASDAQ: RWLK) shares took a step back on Monday after the firm announced that it would be pricing a registered direct offering for $5 million. This comes ...
Read Full Story »

The Pot Industry Will Soon Employ As Many People As the US Army

Cannabis, commonly known as marijuana, is legal for recreational use in 10 states and for medical use in 38. Growing, processing and selling cannabis has become a large enough business ...
Read Full Story »

5 ASCO Winners That Could Still More Than Double

The 55th annual meeting of the American Society of Clinical Oncology (ASCO) has just concluded, and there were some significant moves we saw as a result. Wedbush took a closer ...
Read Full Story »

Why Merrill Lynch Has High Hopes for Cronos

Cronos Group Inc. (NASDAQ: CRON) shares popped on Wednesday after Merrill Lynch released a very positive report. This is not something that happens every day, but the brokerage firm issued ...
Read Full Story »

Is InflaRx Sunk by a Midstage Skin Condition Study?

InflaRx N.V. (NASDAQ: IFRX) shares were destroyed on Wednesday after the firm announced results from its midstage trial in patients suffering from moderate to severe hidradenitis suppurativa (HS). Prior to ...
Read Full Story »

How ReWalk’s Exo-Suit Is Breaking the Mold for Stroke Survivors

ReWalk Robotics Ltd. (NASDAQ: RWLK) shares absolutely exploded on Wednesday on news that the U.S. Food and Drug Administration (FDA) has cleared the firm's ReStore soft exo-suit system for sale ...
Read Full Story »

Why Genocea’s Neoantigen Treatment Is Such a Big Hit at ASCO

Genocea Biosciences Inc. (NASDAQ: GNCA) is one of the big winners from the annual meeting of the American Society of Clinical Oncology (ASCO). The firm announced best-in-class clinical results from ...
Read Full Story »

Meet One of ASCO’s First Losers

Turning Point Therapeutics Inc. (NASDAQ: TPTX) shares dipped on Friday after the firm posted interim data for its midstage study in ROS1-positive non-small cell lung cancer patients. The data came ...
Read Full Story »

Ben & Jerry’s Plans to Offer CBD-Infused Ice Cream

Major consumer products makers that sell beverages, food, and even tobacco have been developing products containing cannabidiol (CBD) in the belief (or is it hope?) that the U.S. government will ...
Read Full Story »

Why Cara Therapeutics Could Rise Another 50%

Cara Therapeutics Inc. (NASDAQ: CARA) recently announced data from its late-stage trial in patients with chronic kidney disease (CKD). While there was a very positive reaction among investors, one analyst ...
Read Full Story »

AstraZeneca Cuts Almost All Ties to Inovio Pharma

Inovio Pharmaceuticals Inc. (NASDAQ: INO) shares dipped on Wednesday after it was announced that the firm’s partnership with AstraZeneca PLC (NASDAQ: AZN) would be scaled back. AstraZeneca subsidiary MedImmune is ...
Read Full Story »

America’s Unsafe Medical Products

The U.S. Food and Drug Administration (FDA) has issued eight new safety alerts, comprising six related to product recalls, including one for an animal antibiotic; one regarding mortality rate among ...
Read Full Story »

What This Cara Therapeutics Late-Stage Study Could Mean for Chronic Kidney Disease

Cara Therapeutics Inc. (NASDAQ: CARA) shares jumped on Wednesday after the firm announced topline data from its late-stage trial in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). Specifically, ...
Read Full Story »

Is This Kezar Life Sciences Lupus Study in Trouble?

Kezar Life Sciences Inc. (NASDAQ: KZR) shares were absolutely crushed on Tuesday after the firm revealed data from its midstage trial in patients with systemic lupus erythematosus (SLE). The data ...
Read Full Story »

Short Sellers Get Even Higher on Cannabis Stocks

Cannabis stocks had a huge showing on Wall Street last fall. In fact, most of the news flow surrounding these stocks had investors pouring money into them. Some of the ...
Read Full Story »